sodium aescinate
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
2
Earliest trial started Jan 9, 2020 (NCT04247659)
Timeline
Indications
Approved for
Mechanism of action
- Transforming protein RhoAINHIBITOR
RHOA inhibitor
- Rho-associated protein kinase 1INHIBITOR
ROCK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07244029 | N/A | Dec 1, 2025 | Oman Medical Board Specialty (OMSB) |
| NCT07304882 | Phase 3 | Nov 30, 2023 | University of Science and Technology, Yemen |
| NCT05263167 | Phase 4 | Mar 15, 2022 | Capital Medical University |
| NCT04322344 | Phase 2/Phase 3 (Phase 3) | Mar 23, 2020 | Azienda Ospedaliera Policlinico "Mater Domini", Magna Graecia University |
| NCT04247659 | Phase 4 | Jan 9, 2020 | Hebei University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Azienda Ospedaliera Policlinico "Mater Domini" | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hebei University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Magna Graecia University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Oman Medical Board Specialty (OMSB) | Government | 1 | 1 | 1 | 2025 |
| University of Science and Technology, Yemen | Academic/Hospital | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1